Acta Scientific Dental Sciences

Editorial Volume 10 Issue 8

Regenerative Dentistry – A Current Overview of Dental Medications Utilized for Rejuvenation.

Nanda Kishore Ghoshal*

Assistant Professor, Department of Dental Hygiene and Dental Technique, India

*Corresponding Author: Nanda Kishore Ghoshal, Assistant Professor, Department of Dental Hygiene and Dental Technique, India.

Received: June 29, 2026; Published: July 06, 2026

Regenerative dentistry harnesses the body’s natural healing processes to mend or restore damaged or unhealthy oral tissues. Unlike conventional restorative dentistry that focuses on replacing lost structures, regenerative dentistry aims to regenerate them. Utilizing concepts from tissue engineering, stem cell therapy, and growth factor application, this discipline strives to repair a range of tissues, such as dentin, enamel, and periodontal structures. This brief note aims to shed light on certain medications that demonstrate regenerative properties, which stimulate pluripotent cells in the pulp and periodontium to rejuvenate dental tissues through clinical trials. Tideglusib is a thiadiazolidinone that serves to inhibit neurodegeneration and inflammation. In human neuroblastoma cells and murine primary neurons, it permanently inhibits GSK-3, reduces tau phosphorylation, and prevents apoptosis. Additionally, it promotes stem cell activity and activates the Wnt/-cat signaling pathway to facilitate recovery. Administering tideglusib at the site of dental damage may trigger this pathway, enabling stem cells to generate reparative dentin and naturally restore the affected dentin. Currently, tideglusib is under investigation for its potential application in various neurodegenerative disorders, particularly Alzheimer’s disease. In a study conducted by Cao., et al. (2022), bioactive glass nanoparticles loaded with tideglusib (tideglusib-BgNPs) were synthesized and incorporated at varying concentrations into calcium silicate cement to evaluate their physiomechanical and bioactive properties in comparison to biodentine, which served as the control. The calcium silicate cement containing 10 weight percent tideglusib-BgNPs exhibited physiomechanical properties that were comparable to those of biodentine. Furthermore, the most significant finding was that the evaluation of cytotoxicity and bioactivity—assessed through cell proliferation, wound healing, and cell migration assays— demonstrated enhanced bioactivity, characterized by improved wound healing, increased proliferation, and superior migration of human dental pulp stem cells compared to biodentine. Dental pulp stem cells (DPSCs) play a vital role in the regeneration of periodontal tissue; however, their therapeutic efficacy is constrained by inadequate osteogenic differentiation. Liraglutide (LIRA), an agonist of the glucagon-like peptide-1 receptor, demonstrates anti-inflammatory effects and protective qualities for bone health in different studies. Periodontitis resulted in heightened infiltration of inflammatory cells, a rise in macrophage accumulation, and increased gene expression levels of tumor necrosis factor-α and inducible nitric oxide synthase within the gingiva, all of which were mitigated through the use of liraglutide. This exceptional property encourages it’s use in Micro Drug Delivery systems (MDD) in Periodontal issues. Metformin, a well-established anti-diabetic medication, has been shown to activate the AMPK signaling pathway, encouraging mesenchymal stem cells, such as dental pulp stem cells and periodontal ligament stem cells, to generate new bone and dentin. It also plays a critical role in suppressing prolonged inflammatory markers like IL-1β, which significantly impede tissue recovery during conditions such as periodontitis. Furthermore, metformin enhances the expression of key genes involved in dentin and bone synthesis, including RUNX2, DMP1, and DSPP. Current research is exploring the use of metformin-loaded biomaterial scaffolds and topical gels to recruit stem cells and facilitate bone regeneration in deep periodontal pockets. Additionally, innovative formulations of metformin-incorporated resins have shown promise in treating tooth root caries while promoting the regeneration of surrounding periodontal tissues. Mecsina (herbal extract) was studied by Aydin., et al. in combination with xenogeneic graft material (bovine bone graft). As an effective bone formation agent, Mecsina Hemostopper increased cell proliferation. Mecsina was found to be an effective option in the augmentation of critical-size defects in rats when combined with xenogeneic bone grafts. Naringin is a compound found in Rhizoma drynariae that inhibits retinoic acid-induced osteoporosis in rats, stimulates bone formation, and increases BMP-2. Radiographic bone density and the area around titanium implants were evaluated in micro Implants placed in the tibia of rats. Rasouli-Ghahroudi., et al. studied the effects of the herbal selenium medicine Semelil. It promotes new bone formation when used with semelil (ANGIPARS) and Bio-Oss. None of the groups showed foreign body reaction (FBR). Combining ANGIPARS with Bio-Oss increased bone formation and maturation, proving that it works synergistically. Providing osteogenic properties to osteoconductive and space-maintaining materials like Bio-Oss may be possible. These findings may be a breakthrough in implant dentistry and maxillofacial defect restoration. These medications are currently being utilized in clinical trials aimed at regenerating dental tissues. While they do not replace restorative dentistry, they could represent a significant advancement in the field of regenerative medicine. If successfully applied in clinical dentistry, this could transform community dental health and complement restorative dentistry. But more extensive trial and large sample population is necessary to establish and to introduce them in dental practice.

Citation

Citation: Nanda Kishore Ghoshal. “Regenerative Dentistry – A Current Overview of Dental Medications Utilized for Rejuvenation". Acta Scientific Dental Sciences 10.8 (2026): 01-02.

Copyright

Copyright: © 2026 Nanda Kishore Ghoshal. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.278

Indexed In





News and Events


  • Publication Certificate
    Authors will be provided with the Publication Certificate after their successful publication
  • Last Date for submission
    Authors are requested to submit manuscripts on/before July 20, 2026, for the upcoming issue of 2026.

Contact US









ff

© 2024 Acta Scientific, All rights reserved.